A critical analysis of barriers to the clinical implementation of pharmacogenomics

Ross A McKinnonSansom Institute, School of Pharmacy and Medical Sciences, University of South AustraliaAdelaide, SA, AustraliaCorrespondence[email protected]

Michael B WardSansom Institute, School of Pharmacy and Medical Sciences, University of South AustraliaAdelaide, SA, Australia

Michael J SorichSansom Institute, School of Pharmacy and Medical Sciences, University of South AustraliaAdelaide, SA, Australia

Pages 751-759 | Published online: 24 Dec 2022

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

AlmarsdottirABBjornsdottirITraulsenJMA lay prescription for tailor-made drugs - focus group reflections on pharmacogenomicsHealth Policy2005712334115607385
PubMed Web of Science ®Google Scholar
AlmueteVIDrug therapy and pharmacogenomics. AphA 2000 – American Pharmaceutical Association Annual Meeting Available from URL: http://www.medscape.com/viewarticle/419158
Google Scholar
BrockTPFaulknerCMWilliamsDMContinuing-education programs in pharmacogenomics for pharmacistsAm J Health-Syst Pharm200259722511977857
PubMed Web of Science ®Google Scholar
DanzonPTowseAThe economics of gene therapy and of pharmacogeneticsValue Health2002551311873384
PubMed Web of Science ®Google Scholar
BuckleyPMcKinnonRAPharmacogenomics, ethics and the communityAustralian Pharmacist200423224
Google Scholar
CarlsonCSEberleMARiederMJSNP and haplotype variation in the human genomeMutat Res2003526536112714183
PubMed Web of Science ®Google Scholar
CarlsonCSEberleMARiederMJAdditional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humansNature Genet2003335182112652300
PubMed Web of Science ®Google Scholar
CarlsonCSEberleMARiederMJSelecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibriumAm J Hum Genet2004741062014681826
PubMed Web of Science ®Google Scholar
CrawfordDCCarlsonCSRiederMJHaplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populationsAm J Hum Genet2004746102215015130
PubMed Web of Science ®Google Scholar
EnsomMHChangTKPatelPPharmacogenetics: the therapeutic drug monitoring of the future?Clin Pharmacokinet20014078380211735602
PubMed Web of Science ®Google Scholar
GardinerSJBeggEJPharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?Pharmacogenet Genomics200515365915864139
PubMed Web of Science ®Google Scholar
GurwitzDLunshofJEDedoussisGPharmacogenomics education: international society of pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of educationPharmacogenomics J200554221515852053
PubMed Web of Science ®Google Scholar
HamptonTFDA seeks genome-based drug dataJAMA-J Am Med Assoc2005291323
Web of Science ®Google Scholar
LazarouJPomeranzBHCoreyPNIncidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studiesJAMA-J Am Med Assoc199827912005
PubMed Web of Science ®Google Scholar
LeeSSRacializing drug design: implications of pharmacogenomics for health disparitiesAm J Public Health2005952133816257939
PubMed Web of Science ®Google Scholar
LewisBPShihIHJones-RhoadesMWPrediction of mammalian microRNA targetsCell20031157879814697198
PubMed Web of Science ®Google Scholar
McGovernDPvan HeelDANegoroKFurther evidence of IBD5/CARD15 (NOD2) epistasis in the susceptibility to ulcerative colitisAm J Hum Genet2003731465614655097
PubMed Web of Science ®Google Scholar
MeyerUAPharmacogenetics - five decades of therapeutic lessons from genetic diversityNature Rev Genet200456697615372089
PubMed Web of Science ®Google Scholar
NebertDWJorge-NebertLVesellESPharmacogenomics and “individualized drug therapy”: high expectations and disappointing achievementsAm J Pharmacogenomics200333617014672516
PubMedGoogle Scholar
NebertDWMenonAGPharmacogenomics, ethnicity, and susceptibility genesPharmacogenomics J20011192211913722
PubMedGoogle Scholar
NebertDWVesellESAdvances in pharmacogenomics and individualized drug therapy: exciting challenges that lie aheadEur J Pharmacol20045002678015464039
PubMed Web of Science ®Google Scholar
PhillipsKAVeenstraDLOrenEPotential role of pharma-cogenomics in reducing adverse drug reactions: a systematic reviewJAMA-J Am Med Assoc200128622709
PubMed Web of Science ®Google Scholar
SalisburyBAPungliyaMChoiJYSNP and haplotype variation in the human genomeMutat Res2003526536112714183
PubMed Web of Science ®Google Scholar
SansgirySSKulkarniASThe human genome project: assessing confidence in knowledge and training requirements for community pharmacistsAm J Pharm Edu200367219
Web of Science ®Google Scholar
ShahJCriteria influencing the clinical uptake of pharmacogenomic strategiesBr Med J20043281482615205293
PubMed Web of Science ®Google Scholar
SchmeddersMFeuersteinGKollekRProspects and limits of pharmacogenetics: The thiopurine methyl transferase (TMPT) experienceAm J Pharmacogenomics200331495512814323
PubMedGoogle Scholar
SchramkeVAllshireRHairpin RNAs and retrotransposon LTRs effect RNAi and chromatin-based gene silencingScience200330110697412869699
PubMed Web of Science ®Google Scholar
StoreyJDTibshiraniRStatistical significance for genomewide studiesProc Natl Acad Sci USA20031009440512883005
PubMed Web of Science ®Google Scholar
TateSKGoldsteinDBWill tomorrow’s medicines work for everyone?Nature Genet20043611 SupplS344215508001
PubMed Web of Science ®Google Scholar
TuckerGPharmacogenetics-expectations and realityBr Med J20043294615231589
PubMed Web of Science ®Google Scholar
Van AkenJPhillipsKAVeenstraDAn introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomicsPharmacogenomics20034231912718713
PubMed Web of Science ®Google Scholar
The International Hap Map ConsortiumThe international HapMap projectNature20034267899514685227
PubMed Web of Science ®Google Scholar
The International Hap Map ConsortiumA haplotype map of the human genomeNature2005437129932016255080
PubMed Web of Science ®Google Scholar
VeenstraDLHigashiMKPhillipsKAAssessing the cost-effectiveness of pharmacogenomicsAAPS Pharmsci20002E2911741245
PubMedGoogle Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

A critical analysis of barriers to the clinical implementation of pharmacogenomics

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A critical analysis of barriers to the clinical implementation of pharmacogenomics

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date